Brief: SymBio Pharmaceuticals says arbitration against The Medicines Company
13/11/2017 06:50
Nov 13 (Reuters) - SymBio Pharmaceuticals Ltd 4582.T
* Says co initiated an arbitration against The Medicines
Company
(MDCO) on Oct. 11, under the rules of International Chamber of
Commerce, seeking damages arising out of MDCO's repudiation of
the license agreement entered into between the co and MDCO on
October 5, 2015, for the exclusive rights to develop and
commercialize the patient-controlled pain management drug "SyB
P-1501" (or "IONSYS") in Japan
* Says the co seeks damages of $82 million (about 9 billion
yen)
Source text in Japanese: https://goo.gl/hwXAJn
Further company coverage: 4582.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))